Article (Scientific journals)
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
Nagler, A.; Baron, Frédéric; Labopin, M. et al.
2021In Bone Marrow Transplantation, 56, p. 218-224
Peer Reviewed verified by ORBi
 

Files


Full Text
s41409-020-01005-y.pdf
Publisher postprint (1.13 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundred had a formal strategy for routine MRD assessment, 91 for both ALL and AML. For ALL (n = 95), assessing MRD has been routine practice starting from 2010 (range, 1990–2019). Techniques used for MRD assessment consisted of PCR techniques alone (n = 27), multiparameter flow cytometry (MFC, n = 16), both techniques (n = 43), next-generation sequencing (NGS) + PCR (n = 2), or PCR + MFC + NGS (n = 7). The majority of centers assessed MRD every 2–3 months for 2 (range, 1-until relapse) years. For AML, assessing MRD was routine in 92 centers starting in 2010 (range 1990–2019). Assessment of MRD was by PCR (n = 23), MFC (n = 13), both PCR and MFC (n = 39), both PCR and NGS (n = 3), and by all three techniques (n = 14). The majority assesses MRD for AML every 2–3 months for 2 (range, 1-until relapse) years. This survey is the first step in the aim to include MRD status as a routine registry capture parameter in acute leukemia. © 2020, The Author(s), under exclusive licence to Springer Nature Limited.
Disciplines :
Hematology
Author, co-author :
Nagler, A. ;  Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Tel Aviv, Israel, EBMT ALWP Office, Saint Antoine Hospital, Paris, France
Baron, Frédéric   ;  Université de Liège - ULiège > I3-Hematology
Labopin, M.;  EBMT Paris Study Office/CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Paris, France, Sorbonne University, Paris, France
Polge, E.;  EBMT Paris Study Office/CEREST-TC, Paris, France
Esteve, J.;  Hematology Department, Hospital Clinic, Barcelona, Spain
Bazarbachi, A.;  Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
Brissot, E.;  Department of Haematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Paris, France, Sorbonne University, Paris, France
Bug, G.;  Medizinische Klinik II, Hämatologie, Medizinische Onkologie, Goethe-Universitaet, Frankfurt, Germany
Ciceri, F.;  Ospedale San Raffaele S.r.l., Haematology and BMT, Milan, Italy
Giebel, S.;  Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice, Poland
Gilleece, M. H.;  Yorkshire Blood and Marrow Transplant Programme, Haematology Department, St James’s Institute of Oncology, Leeds, United Kingdom
Gorin, N.-C.;  Department of Haematology, Saint Antoine Hospital, Paris, France
Lanza, F.;  Hematology Unit, Romagna Transplant Network, Ravenna, Italy
Peric, Z.;  Bone Marrow Transplant Unit, University Hospital Center Rebro, Zagreb, Croatia
Ruggeri, A.;  Ospedale San Raffaele S.r.l., Haematology and BMT, Milan, Italy
Sanz, J.;  Hematology Department, University Hospital La Fe, Valencia, Spain
Savani, B. N.;  Department of Hematology–Oncology, Vanderbilt University Medical Center, Nashville, TN, United States
Schmid, C.;  Klinikum Augsburg, II Medizinische Klinik, Augsburg, Germany
Shouval, R.;  Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States, Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel
Spyridonidis, A.;  BMT Unit, University Hospital of Patras, Patras, Greece
Versluis, J.;  Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
Mohty, M.;  EBMT Paris Study Office/CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France, INSERM UMR 938, Paris, France, Sorbonne University, Paris, France
More authors (12 more) Less
 These authors have contributed equally to this work.
Language :
English
Title :
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT
Publication date :
2021
Journal title :
Bone Marrow Transplantation
ISSN :
0268-3369
eISSN :
1476-5365
Publisher :
Springer Nature
Volume :
56
Pages :
218-224
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Available on ORBi :
since 03 September 2020

Statistics


Number of views
114 (5 by ULiège)
Number of downloads
278 (4 by ULiège)

Scopus citations®
 
31
Scopus citations®
without self-citations
9
OpenCitations
 
20

Bibliography


Similar publications



Contact ORBi